Nutriband files provisional patent application to enhance its AVERSA™ transdermal abuse deterrent technology being developed for patches containing opioids and stimulants with a potential for abuse.
Nutriband Inc. announced it has received a Notice of Allowance from the USPTO for its patent application regarding the Aversa™ abuse deterrent technology, which is designed to prevent the misuse and ...
Expands Global Intellectual Property Portfolio Supporting Long-Term Revenue Growth VANCOUVER, BC / ACCESS Newswire / January 7, 2026 / Ovation Science Inc. (CSE:OVAT)(OTC PINK:OVATF) ("Ovation" or the ...
Nutriband’s abuse-deterrent platform technology is now patented in 46 countries and territories covering major global markets. Nutriband (NTRB) is targeting to file for FDA approval for AVERSA™ ...
ORLANDO, Fla., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ: NTRB) (NASDAQ: NTRBW) ("Nutriband" or the "Company"), a developer of transdermal pharmaceutical products including ...
Independent analysis examines why 'natural Ozempic alternative' and 'berberine weight loss patch' searches are driving ...
Love Pharma has struck a deal to acquire transdermal drug delivery technology, signing a letter of intent to buy Naltrexone Therapeutics for intellectual property covering the administration of a ...
Independent Report Examines Collagen Patch Benefits, Delivery Science, and What Consumers Evaluate — With Invig+ as Category ReferenceNEW YORK, NY, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Disclaimer: This ...
Notice of Allowance received from Chinese National Intellectual Property Administration (CNIPA) for the patent application covering its Platform AVERSA™ abuse deterrent transdermal technology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback